Pathological findings in 2 cases of fatal 25I-NBOMe toxicity

American Journal of Forensic Medicine and Pathology

Volumn 35, Issue 1, 2014, Pages 20-25

  Walterscheid, Jeffrey P ^a   Phillips, Garrett T ^a   Lopez, Ana E ^a   Gonsoulin, Morna L ^a   Chen, Hsin Hung ^a   Sanchez, Luis A ^a  

^a Harris County Institute of Forensic Sciences   (United States)

Author keywords

25I NBOM.E.; 2C I NBOM.E.; CIMBI 5; synthetic designer drug

Indexed keywords

2 (4 IODO 2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYL)ETHANAMINE; 2-(4-IODO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL)ETHANAMINE; BENZYLAMINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN 2 AGONIST;

ADDICTION; ADOLESCENT; ARTICLE; BLOOD; CASE REPORT; CONTUSION; ECCHYMOSIS; FEMALE; FORENSIC TOXICOLOGY; HEMATOMA; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METHODOLOGY; PATHOLOGY; PURPURA; URINE; VIOLENCE; YOUNG ADULT;

ADOLESCENT; BENZYLAMINES; CHROMATOGRAPHY, LIQUID; CONTUSIONS; ECCHYMOSIS; FEMALE; FORENSIC TOXICOLOGY; HALLUCINOGENS; HEMATOMA; HUMANS; MALE; MASS SPECTROMETRY; PHENETHYLAMINES; PURPURA; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SUBSTANCE-RELATED DISORDERS; VIOLENCE; YOUNG ADULT;

EID: 84894491132     PISSN: 01957910     EISSN: 1533404X     Source Type: Journal    
DOI: 10.1097/PAF.0000000000000082     Document Type: Article

References (23)

1. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008;75:17-33.
2. Braun U, Shulgin AT, Braun G, et al. Synthesis and body distribution of several iodine-131 labeled centrally acting drugs. J Med Chem. 1977;20:1543-1546.
3. Braden MR, Parrish JC, Naylor JC, et al. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70:1956-1964.
4. Ettrup A, Hansen M, Santini MA, et al. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging. 2011;38:681-693.
5. Ettrup A, Palner M, Gillings N, et al. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med. 2010;51:1763-1770.
6. Nichols DE, Frescas SP, Chemel BR, et al. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy- 4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.Bioorg Med Chem. 2008;16:6116-6123.
7. Guale F, Shahreza S, Walterscheid JP, et al. Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol. 2013;37:17-24.
8. Rao VJ, Wetli CV. The forensic significance of conjunctival petechiae. Am J Forensic Med Pathol. 1988;9:32-34.
9. Lorin de la Grandmaison G, Fermanian C, Durigon M. Analysis of discrepancies between external body examination and forensic autopsy. Am J Forensic Med Pathol. 2008;29:40-42.
10. Drees JC, Stone JA, Wu AH. Morbidity involving the hallucinogenic designer amines MDA and 2C-I. J Forensic Sci. 2009;54:1485-1487.
11. Acuna-Castillo C, Villalobos C, Moya PR, et al. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol. 2002;136:510-519.
12. Blaazer AR, Smid P, Kruse CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. ChemMedChem. 2008;3:1299-1309.
13. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131-181.
14. McCall RB, Clement ME. Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system. Pharmacol Rev. 1994;46:231-243.
15. McCall RB, Patel BN, Harris LT. Effects of serotonin1 and serotonin2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmacol Exp Ther. 1987;242:1152-1159.
16. Ramage AG. Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res Bull. 2001;56:425-439.
17. Ramage AG, Villalon CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci. 2008;29:472-481.
18. Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007;376:45-63.
19. Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila). 2013;51:174-177.
20. Silva ME, Heim R, Strasser A, et al. Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J Comput Aided Mol Des. 2011;25:51-66.
21. Trachsel D, Nichols DE, Kidd S, et al. 4-aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities. Chem Biodivers. 2009;6:692-704.
22. Zuba D, Sekula K, Buczek A. 25C-NBOMeVnew potent hallucinogenic substance identified on the drug market. Forensic Sci Int. 2012;227:7-14.
23. Zuba D, Sekula K. Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Test Anal. 2013;5,8:634-645.